Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States

The head-to-head AIDS Clinical Trial Group (ACTG) 5257 clinical trial found raltegravir (RAL) to be superior to atazanavir + ritonavir (ATV/r) and darunavir + ritonavir (DRV/r), when used in combination with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) by treatment-naive adults with HIV-1 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Brogan, Anita J., Davis, Ashley E., Goodwin, Bridgett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117059/
https://www.ncbi.nlm.nih.gov/pubmed/30161205
http://dx.doi.org/10.1371/journal.pone.0203293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117059/
https://www.ncbi.nlm.nih.gov/pubmed/30161205
http://dx.doi.org/10.1371/journal.pone.0203293

Ejemplares similares